Connect with us

Featured

Stock Price Morning Update – July 22, 2019

Joe Samuel

Published

on

Gold Prices Have Investors Scrambling & Analysts Clamoring For Junior Gold Stocks

Gold has long been a safe haven stock. But as the market turned toward tech, precious metal stocks took a back seat…until now. Could the timing of gold’s next bull run be perfect right now?

Continue Reading


PharmaCyte Biotech (PMCB) and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes

PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced it has entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes with the potential to express higher levels of insulin.

Read The Full Release


ROKU Stock Price Hits Another Life Time High: Good News For Tech Stocks?

In 2019 alone, the stock has risen by as much as 271% as the company continued to add new customers and boosted revenues from advertising. However, could the latest surge be a signal for the next bull market in tech?

See For Yourself


Two Massive Growth Industries, One Choice for Investors

These two industries are at the epicenter of growth and investors aren’t being shy about their appetite for companies in these arenas. But one company, in particular, has developed a unique business model that services both of these massive growth industries.

Click To Read More


adbe stock price twlo stock price

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading
Click to comment

Biotechnology

StockPrice.com Subscribers WIN BIG!

Jon Phillip

Published

on

stock price WINNING

We owe you a BIG congratulations. The whole point of StockPrice.com is to bring you important information, first. Sure we send emails out every day on top trending articles and news but we also bring periodic reports on certain companies.

Earlier this year we brought you a full report on a company, PharmaCyte Biotech (PMCB).

Since that report, we’ve watched as PharmaCyte evolved into what it has become today: a biotech powerhouse on the verge of presenting its treatment to the FDA!

Stock Price Subscribers Saw The Full PMCB 90%+ Breakout From August – December; Congratulations! Click Here to Read Our Original Report

This is a great thing for subscribers and we’ve got more featured reports coming! How do you get these reports first?


STEP 1: Make Sure Our Email Address Is In Your Whitelist Address Book So Nothing Gets Lost In Spam

STEP 2:Take Out Your Cell Phone And Text “STOCKPRICE” to 63566. Even If You Miss An Email, We Send Out Updates Directly To Your Cell Phone In Real Time

Again, congratulations to everyone and make sure you stay tuned for our next Stock Price Exclusive Report!




Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Continue Reading

Featured

Stock Price Newsletter – December 12, 2019

Joe Samuel

Published

on

penny stocks news

Are These Biotech Stocks To Buy Or Sell Right Now?

One of the sectors that have proven to be a consistently steady performer in the stock market over the past few years is the biotech sector. Hence, it is not really a surprise that investors are almost always on the lookout for the next big thing among biotech stocks.

Click To Read More


The $40 Billion Dollar Content Gold Rush

Apple, Disney, Netflix, Amazon, NBC, Hulu & More are All Competing Within the Global Video Streaming Market and They All Need the Same Thing… New & Original Content! Massive Demand May Create Huge Opportunity for One Company.

See For Yourself


3 Penny Stocks To Watch Before The End of 2019: One Up 308%

Penny stocks have often proven to be one of the best classes of stocks to invest in if you like high risk. These cheap stocks allow investors to get into the stock market with a small capital account and buy thousands or even millions of shares of stock at a time. Since these low priced stocks tend to move by pennies at a time, that slight change can equate to large percentage moves.

Continue Reading

Continue Reading

Featured

3 Penny Stocks To Watch Before The End of 2019: One Up 308%

Jon Phillip

Published

on

stocks to buy now

Penny stocks have often proven to be one of the best classes of stocks to invest in if you like high risk. These cheap stocks allow investors to get into the stock market with a small capital account and buy thousands or even millions of shares of stock at a time. Since these low priced stocks tend to move by pennies at a time, that slight change can equate to large percentage moves.

That being said, investors need to keep in mind that research is key. That’s in order to discover potentially winning trades in the market. Here is a look at the list of penny stocks that could end up on some watch lists this month.

Penny Stocks To Watch #1: Iterum Therapeutics

stocks to watch Iterum Therapeutics

One of the penny stocks that made a significant move on Tuesday was that of Iterum Therapeutics PLC (ITRM Stock Report) and the move came about after the company made a major announcement. The company announced that the Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial of its product managed to hit the endpoint set by the United States Food and Drug Administration.

The medicine in question is meant for the treatment of complex inter-abdominal infections. The news proved to be a highly positive one for the company and the market thought so as well. ITRM stock rallied by as much as 22% after the news broke and Iterum has emerged as one of the companies that could be tracked for the rest of the week.

Penny Stocks To Watch #2 Technical Communications

stocks to watch Technical Communications Corporation

The other penny stock that went on a massive rally on Tuesday is the Technical Communications Corporation (TCCO Stock Report) stock. The rally came about after the company blew analysts’ estimates out of the water in its third quarter and swung back to profit as well.

After having made losses of $239,000 in the year-ago period, Technical Communications reported profits of $1.03 million and that reflects a remarkable turnaround. The company managed to complete a wide range of overseas contracts and that boosted its earnings. TCCO stock has rallied by as much as 308%.

Penny Stocks To Watch #3 Equillium

stocks to watch Equillium Inc

Lastly, Equillium Inc (EQ Stock Report) has emerged as another penny stock that has recorded impressive gains in recent days. Over the past two weeks, EQ stock has gained as much as 47% and on Wednesday it went up by 10% yet again.

Yesterday, the company announced that its Lupus Nephritis treatment Itolizumab has been granted fast track status by the U.S. FDA and that resulted in a rally in the stock as investors flocked to it pretty quickly. It could be a stock worth watching in the coming days.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com